Myoclonic dystonia

Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence

Saturday, May 23, 2020 - 6:00am

The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.

Key Points: 
  • The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.
  • Symptom recurrence significantly impacted patients quality of life, including sleep, relationships, performance of daily tasks and working lives.
  • Eligible participants were over 18 years old and had (or cared for someone with) spasticity or cervical dystonia (CD) treated with BoNT-A for at least one year.
  • How do patients with cervical dystonia (CD) experience their botulinum neurotoxin type a (BoNT-A) treatment cycle: results from an international online survey.

Global Cervical Dystonia Therapeutics Market to 2023: Alternatives to Botulinum Toxins and Other Therapeutics will Provide Market Challenges

Wednesday, November 21, 2018 - 1:00pm

The cervical dystonia therapeutics market will register a CAGR of almost 5% by 2023.

Key Points: 
  • The cervical dystonia therapeutics market will register a CAGR of almost 5% by 2023.
  • With the rise in reimbursement programs for botulinum neurotoxin injections, there is a growing demand for treatment of cervical dystonia.
  • Several reimbursement programs are available to help people access the high-cost botulinum neurotoxin therapy for the treatment of cervical dystonia.
  • The global cervical dystonia therapeutics industry is forecasted to witness a steady growth owing to the expected approval of late-stage molecules in the pipeline for the treatment of cervical dystonia.